Myopathy associated with atorvastatin-ezetimibe combination therapy

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are primary treatments for dyslipidemia.
• Statins are generally well-tolerated, but rare serious adverse effects like rhabdomyolysis can occur.
• Combination therapy for dyslipidemia is increasingly common but may elevate risks.

Observation:

• A patient developed muscle pain and elevated creatine kinase levels 16 days after initiating ezetimibe alongside atorvastatin therapy.
• The patient's symptoms resolved and creatine kinase levels normalized 12 days after discontinuing ezetimibe.

Findings:

• This case highlights a potential adverse drug reaction between high-dose atorvastatin and ezetimibe.
• Muscle pain and elevated creatine kinase levels suggest a possible link to the combination therapy.

Implications:

• The findings suggest that caution and vigilant monitoring are necessary for patients on high-dose atorvastatin and ezetimibe combination therapy.
• Further investigation into the safety profile of this specific combination may be warranted.
• This case underscores the importance of individualized patient monitoring for adverse drug events.